Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial
2019 · The Lancet Infectious Diseases · 190 citations
https://doi.org/10.1016/s1473-3099(19)30279-8